Novavax

Yahoo Finance • 3 days ago

Report on COVID vaccine benefits being delayed at CDC: WaPo

[CDC Centers for Disease Control and Prevention] The acting director of the Centers for Disease Control and Prevention, Jay Bhattacharya, has delayed the publication of a CDC report indicating that COVID vaccines cut the risk of ER visits... Full story

Yahoo Finance • 4 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Wednesday afternoon, with the NYSE Health Care Index adding 1.6% and th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 4 days ago

3 Reasons NVAX is Risky and 1 Stock to Buy Instead

Over the last six months, Novavax shares have sunk to $8.21, producing a disappointing 7.7% loss - worse than the S&P 500’s 2.1% drop. This might have investors contemplating their next move. Is there a buying opportunity in Novavax, or d... Full story

Yahoo Finance • 5 days ago

Shah Capital intends to vote against Novavax's board nominees, executive compensation

By Sneha S K and Sriparna Roy April 8 (Reuters) - Activist investor Shah Capital plans to vote against the re-election of board nominees and ‌the executive compensation package at Novavax's upcoming annual meeting, renewing ‌pressure for... Full story

Yahoo Finance • 11 days ago

2 Growth Stocks Set to Flourishand 1 We Question

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajec... Full story

Yahoo Finance • 21 days ago

2 Healthcare Stocks to Target This Week and 1 That Underwhelm

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the... Full story

Yahoo Finance • 22 days ago

Trump administration reportedly shortlisting CDC nominees

[Centers for disease control and prevention sign] sshepard Two physicians with somewhat contrasting views on vaccines are among the potential candidates the Trump administration is considering as its pick to lead the U.S. Centers for Dise... Full story

Yahoo Finance • last month

Winners And Losers Of Q4: Biogen (NASDAQ:BIIB) Vs The Rest Of The Therapeutics Stocks

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next few years, therapeutic companies, which develop a wide variety of treatments for... Full story

Yahoo Finance • last month

FDA vaccine chief to leave the agency again

[FDA Headquarters] For the second time in less than a year, Vinay Prasad, the head of the U.S. Food and Drug Administration’s vaccines unit, is leaving the agency, according to a statement from the FDA commissioner, Marty Makary. Prasad... Full story

Yahoo Finance • last month

Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmaceutical companies, including major globa... Full story

Yahoo Finance • 2 months ago

Pfizer Taps Novavax Matrix-M To Refresh Vaccine Growth Story

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Pfizer, NYSE:PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant t... Full story

Yahoo Finance • 4 months ago

Moderna Slammed By 'Fear, Confusion' After FDA Alleges Covid Shots Killed 10

Moderna and other vaccine stocks tumbled Monday after an FDA director reportedly issued a memo that says Covid shots killed 10 children. Continue Reading View Comments... Full story

Yahoo Finance • 4 months ago

Nvidia's Synopsys investment, Disney stock pops on Zootopia 2

Yahoo Finance host Julie Hyman kicks off Yahoo Finance's Market Minute with some of the top stories of Monday's trading session, including Nvidia's (NVDA) investment in Synopsys (SNPS), Disney's (DIS) "Zootopia 2," and vaccine stock moves.... Full story

Yahoo Finance • 4 months ago

Shares of vaccine makers drop after FDA memo flags reports of child deaths

Investing.com -- Shares in major COVID-19 vaccine makers fell on Monday after an internal U.S. Food and Drug Administration (FDA) memo reportedly suggested that vaccinations may have contributed to several child deaths linked to heart infl... Full story

Yahoo Finance • 4 months ago

FDA official Prasad says COVID shot deaths mean stricter vaccine approval standards

[Doctor Vaccinating Little Girl Close Up] SeventyFour/iStock via Getty Images Vinay Prasad, the head of the US FDA's Center for Biologics Evaluations and Research which oversees vaccines, said that future vaccine approvals will face stric... Full story

Yahoo Finance • 5 months ago

January 2026 Options Now Available For Novavax (NVAX)

Investors in Novavax, Inc. (Symbol: NVAX) saw new options become available today, for the January 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVAX options chain for the new January 2026 co... Full story

Yahoo Finance • 5 months ago

Vaccine critic selected as CDC deputy director

[CDC Headquarters] hapabapa Ralph Abraham, Louisiana's surgeon general, is the CDC's next deputy director. _The Washington Post_, which broke [https://www.washingtonpost.com/health/2025/11/25/cdc-new-deputy-vaccine-ralph-abraham/] the de... Full story

Yahoo Finance • 5 months ago

Novavax Shifts From COVID Sales to R&D Focus While Updating 2025 Forecast

Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the company’s continuous strategic shift from... Full story

Yahoo Finance • 5 months ago

Novavax rises after a seven-day slide

Novavax (NVAX [https://seekingalpha.com/symbol/NVAX]) rose 3.70% to close at $6.45 on Friday, snapping a seven-session losing streak, with notable drops of 3.38% and 3.50% on November 18 and 19. Novavax now expects to reach profitability... Full story

Yahoo Finance • 5 months ago

Novavax outlines $1.04B–$1.06B 2025 revenue framework and targets non-GAAP profitability as early as 2028 amid partnership-driven transition

Earnings Call Insights: Novavax (NVAX) Q3 2025 MANAGEMENT VIEW * John Jacobs, President, CEO & Director, stated that Novavax has made significant progress in Q3 by strengthening existing partnerships and building new collaborations whi... Full story